AstraZeneca (AZN) Given “Buy” Rating at Citigroup

Citigroup reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a report published on Monday, Digital Look reports. Citigroup currently has a GBX 7,000 ($91.47) price target on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on AZN. Deutsche Bank reaffirmed a buy rating and set a GBX 6,900 ($90.16) price target on shares of AstraZeneca in a research report on Monday, January 14th. Societe Generale increased their price target on AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the stock a buy rating in a research report on Wednesday, January 16th. Barclays reaffirmed an overweight rating on shares of AstraZeneca in a research report on Monday, January 21st. JPMorgan Chase & Co. reaffirmed a buy rating on shares of AstraZeneca in a research report on Tuesday, January 22nd. Finally, Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research report on Tuesday, February 5th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. AstraZeneca has a consensus rating of Hold and a consensus price target of GBX 6,397.70 ($83.60).

Shares of AZN opened at GBX 5,743 ($75.04) on Monday. The stock has a market cap of $75.19 billion and a price-to-earnings ratio of 30.23. The company has a debt-to-equity ratio of 179.66, a quick ratio of 0.57 and a current ratio of 0.75. AstraZeneca has a fifty-two week low of GBX 5,110 ($66.77) and a fifty-two week high of GBX 6,540 ($85.46).

In related news, insider Philip A. J. Broadley purchased 520 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were purchased at an average cost of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer purchased 8,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The stock was bought at an average cost of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: What is a front-end load?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.